Take a deep dive into #ResMed a global leader in medical device development and cloud-based software. Uncover the story behind ResMed's 35-year rein, its history, operations, financials, and investment potential. Established in 1989 by Dr. Peter Farrell, ResMed is dual-listed on the NYSE and ASX as $RMD. With a primary focus on the US market, constituting 65% of its sales, it gained significant attention in Australia and was one of the most talked about stocks in 2023. Operating globally, ResMed employs 10,000+ people, showcasing a strong tech presence with 9,700 patents.Whether you're a seasoned investor or just dipping your toes, Stock Break is your opportunity to dive into public companies to get a better understanding of their business activity, fundamentals, and potential. Hosted by market analyst Josh Gilbert.Watch on YouTube ? https://www.youtube.com/watch?v=8weT3asOZiMInvest in ResMed ? https://www.etoro.com/markets/rmd.asx